Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Praxis Precision Medicines filings document regulatory disclosures for a CNS-focused biopharmaceutical issuer with common stock listed on the Nasdaq Global Select Market under PRAX. Its Form 8-K and 8-K/A reports cover material events, operating and financial results, clinical and regulatory updates, capital-structure disclosures, and leadership or board changes.
The company’s filing record includes disclosures related to ulixacaltamide HCl for essential tremor, elsunersen in SCN2A developmental and epileptic encephalopathy, and broader pipeline programs in movement disorders and epilepsy. Proxy materials address annual meeting matters, board composition, committee assignments, executive compensation, equity awards and other governance subjects.
Praxis Precision Medicines principal accounting officer Lauren Mastrocola reported an acquisition of company stock through an employee plan. On this Form 4, she acquired 127 shares of Praxis Precision Medicines, Inc. common stock at $167.943 per share. These shares were purchased under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). After this award, she directly holds a total of 13,572.656 common shares.
Praxis Precision Medicines General Counsel and Secretary Alex Nemiroff reported an acquisition of company stock through an employee plan. On this Form 4, Nemiroff received 78 shares of Praxis Precision Medicines common stock at a price of $167.943 per share.
These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). After this award, Nemiroff directly holds a total of 26,010.667 shares of common stock.
Praxis Precision Medicines Chief Financial Officer acquires additional shares through an employee plan. Timothy Edwin Kelly acquired 121 shares of Praxis Precision Medicines common stock at $167.943 per share on May 14, 2026 under the company’s Employee Stock Purchase Plan. Following this award, he directly holds 31,167 common shares.
Praxis Precision Medicines Chief Operating Officer acquires shares through employee plan. Megan Sniecinski acquired 89 shares of Praxis Precision Medicines common stock at an effective price of $167.943 per share under the company’s Employee Stock Purchase Plan. Following this acquisition, she directly holds 28,664 common shares.
Praxis Precision Medicines CEO Marcio Souza reported a routine compensation-related stock acquisition. On May 14, 2026, he acquired 126 shares of Common Stock at $167.943 per share under the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). Following this grant, he directly owns 77,016 shares of Praxis common stock and has an additional 2,600 shares held indirectly through his spouse.
Praxis Precision Medicines Schedules 13G: Baker Bros. Advisors reports 1,753,198 shares (6.3%)
Baker Bros. Advisors LP, together with Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker, reports beneficial ownership of 1,753,198 shares of Praxis Precision Medicines common stock, representing 6.3% of 27,859,514 shares outstanding as of March 31, 2026. Holdings are held indirectly through funds 667, L.P. and Baker Brothers Life Sciences, L.P.; Life Sciences holds 1,622,127 shares and 667 holds 131,071 shares. The filing discloses pre-funded warrants with exercise limits tied to a 4.99% Maximum Percentage (adjustable up to 19.99% with 61-day notice).
Praxis Precision Medicines Schedule 13G/A amendment reports that Point72-related entities and Steven A. Cohen beneficially owned 0.2% of Praxis common stock, representing 65,933 shares, as of the close of business on March 31, 2026. The filing lists shared voting and dispositive power across several Point72 entities and states that Point72 Asset Management and Point72 Capital Advisors directly own no shares but exercise investment or shared power over the reported holdings.
Praxis Precision Medicines, Inc. ownership update: two institutional investors filed an amendment reporting combined beneficial ownership of 2,472,480 shares, representing 8.9% of common stock. The filing lists sole voting and dispositive power of 2,468,413 shares for Orbis Investment Management Ltd and 4,067 shares for Allan Gray Australia Pty Ltd.
The filing classifies both reporting persons as non‑U.S. institutions equivalent to an investment adviser and disclaims group beneficial ownership between them. Signatures certify comparability of foreign regulatory schemes and willingness to furnish Schedule 13D information if requested.
Praxis Precision Medicines reported a first quarter 2026 net loss of $92.6 million, wider than $69.3 million a year earlier, as it ramped spending on late-stage neurology programs. Research and development expenses rose to $78.0 million, with general and administrative costs increasing to $27.9 million.
The company ended March 31, 2026 with $1.4 billion in cash, cash equivalents and marketable securities, up from $926.1 million driven mainly by a January 2026 follow-on offering, and expects this to fund operations into 2028.
FDA accepted NDAs for ulixacaltamide in Essential Tremor and relutrigine in SCN2A/SCN8A DEEs, with PDUFA target action dates on January 29, 2027 and September 27, 2026, respectively. Elsunersen achieved a 77% placebo-adjusted seizure reduction in EMBRAVE Part A, and pivotal epilepsy readouts for vormatrigine and relutrigine’s EMERALD study are expected in 2026.
Praxis Precision Medicines reported a net loss of $92.6M for the three months ended March 31, 2026, driven by heavy investment in its CNS pipeline. Research and development spending rose to $78.0M, while general and administrative costs increased to $27.9M as commercialization planning accelerated.
The company ended the quarter with $1.4B in cash, cash equivalents and marketable securities, boosted by a $621.2M follow-on equity offering completed in January 2026. Management believes this balance can fund operations into 2028 while advancing multiple late-stage programs.
Praxis has submitted NDAs for ulixacaltamide in essential tremor and relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies. The relutrigine filing has FDA priority review with a target PDUFA date of September 27, 2026, and ulixacaltamide has a PDUFA date of January 29, 2027, positioning the company for potential first commercial products.